NEW YORK (GenomeWeb News) – Bayer today said that its Bayer HealthCare business has joined the non-profit Structural Genomics Consortium.

Bayer will provide funding to the consortium to accelerate drug research in the areas of protein science and epigenetics. In addition, it will collaborate with the consortium on research projects to identify small molecules that can interfere with protein activity involved in epigenetic control. Bayer also said that ti will provide a subset of its compound library to the SGC for screening.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.